Rotator cuff tears are a significant health concern that severely affect shoulder joint mobility in patients. Common clinical manifestations of RCTs include shoulder pain, limited range of motion, joint instability, muscle weakness, and functional disability. In patients with rotator cuff tears, the prevalence of vitamin D deficiency ranges from 8.3% to 71%. Given its critical role in muscle strength and function, vitamin D is emerging as an important factor in the management of musculoskeletal disorders, including rotator cuff injuries. Despite the promising evidence regarding vitamin D's role in muscle strength and tendon healing, the specific impact of vitamin D supplementation on postoperative rehabilitation remains unclear. Given that vitamin D deficiency is easily diagnosed and treated, it is considered a modifiable risk factor that could be utilized in orthopedic care to improve patient outcomes. Vitamin D supplementation is a cost-effective and potentially efficient intervention that may enhance muscle strength, reduce postoperative pain, and improve joint function in patients recovering from rotator cuff repair. The objective of this study is to investigate the effects of vitamin D supplementation on postoperative outcomes in patients undergoing arthroscopic rotator cuff repair. The study will be conducted as a randomized controlled trial, with participants receiving either a daily dose of 4000 IU of vitamin D or a placebo. The primary outcomes to be evaluated include muscle strength, postoperative pain, and joint function. Blood samples will be collected at baseline, and after 3 months, 6 months, and 12 months of supplementation to monitor the effects of vitamin D on serum levels and its correlation with clinical outcomes.

Start Date01 Jun 2025

Sponsor / Collaborator

The Chinese University of Hong Kong

NCT06791044

/ Not yet recruitingNot ApplicableIIT

25(OH)-vitamin D and Its Association with Bone Density, Body Composition, Strength, Walking Speed, Physical Performance and Pain in Hospitalized Individuals with Neurological Disorders

The NeuroVitD study aims to assess vitamin D levels in hospitalized cohorts with neurological disorders resulting in motor disabilities, providing epidemiological data necessary for guidelines. The primary objective is to assess vitamin D insufficiency in the neurological populations under investigation and secondary to evaluate the impact of vitamin D supplementation on problems associated with structural and functional parameters.
The NeuroVitD study will be a randomized, cluster, controlled intervention trial lasting 2 years, enrolling 120 individulas, (30 controls), including those with stroke, spinal cord injury, and traumatic brain injury. Comprehensive epidemiological data, including demographic and anthropometric information, will be documented alongside social behaviors such as exercise and smoking. Serum vitamin D levels, bone density, body composition, strength, speed, physical performance and pain will be assessed.
The study will also evaluate the effects of vitamin D supplementation at two distinct dosages: 50,000 I.U of vitamin D weekly for 8 weeks or 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks. Calcium, parathyroid hormone, and phosphorus levels will be assessed to examine the impact of vitamin D administration on additional biochemical markers.
The findings will encompass vitamin D levels, bone density, body composition, strength, walking speed, physical performance and pain. The impact of vitamin D supplementation on various biochemical parameters will be analyzed, along with gender and group comparisons. Correlations will be established based on participants' residential locations, the administration of vitamin D supplementation, seasonal variations, and associations with specific medications for neurological conditions.

Start Date01 Jun 2025

Sponsor / Collaborator-

NCT06964334

/ Not yet recruitingPhase 3IIT

The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection

Helicobacter pylori (H. pylori) is one of the most common chronic infections worldwide. The mode of transmission of H. pylori is through the fecal-oral or oral-oral routes.
Chronic gastritis has been linked to helicobacter pylori (H. pylori) infection. Peptic ulcer disease, gastric adenocarcinoma, and gastric lymphoma are all linked to this condition .
In Egypt, a high prevalence of H. pylori infections has been reported, ranging from 70% in the general population , 73% among school children , up to 88% in patients with chronic active HCV .
In 2007, the American College of Gastroenterology estimated that the cure rate for H. pylori infections was 70-85 percent with the use of a proton pump inhibitor (PPI), clarithromycin, and amoxicillin or metronidazole .
children with H. pylori infection do not have severe digestive symptoms. pylori infection represents a key factor in the pathogenesis of duodenal ulcer and chronic gastritis in children. In addition, H. pylori infection has also been reported to have extra-digestive consequences .
A recent comprehensive evaluation found that sequential and conventional triple treatment had a cure rate of 84% .
The infected macrophage is unable to create enough 1,25-(OH)2D to control the synthesis of AMP cathelicidin when it is vitamin D deficient .
vitamin D has a powerful systemic antibacterial impact by enhancing the activity of monocytes and macrophages. Most illnesses seem to benefit from a vitamin D-rich condition .
Vitamin D-deficient subjects might be more prone to developing H. pylori infection .

Start Date01 Jun 2025

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Colecalciferol

100 Translational Medicine associated with Colecalciferol

100 Patents (Medical) associated with Colecalciferol

30,473

Literatures (Medical) associated with Colecalciferol

31 Dec 2025·Artificial Cells Nanomedicine and Biotechnology

Vitamin D3 loaded polycaprolactone nanoparticles enhance the expression of the antimicrobial peptide cathelicidin in macrophages

Article

Author: Dube, Admire ; Ahmed, Rami ; Khoza, Star ; Dlozi, Prince N.

Tuberculosis (TB), primarily caused by Mycobacterium tuberculosis, remains a global health burden. Current antibiotic treatments are limited by adverse effects, poor adherence, and drug resistance, necessitating new therapeutic approaches. Recent studies highlight the role of vitamin D3 (VD3) in enhancing host immune responses against the mycobacterium via cathelicidin (an antimicrobial peptide) and autophagy activation. In this study, VD3-loaded poly-ƹ-caprolactone (PCL) nanoparticles (NPs) were synthesized to enhance cathelicidin expression in macrophages. NPs containing cholecalciferol, calcifediol, and calcitriol were synthesized using an emulsification solvent-evaporation technique. Average sizes of synthesized NPs ranged from 304.7 to 458.7 nm, with polydispersity index (PDI) and zeta potential (ZP) ranging from 0.103 to 0.257 and -17.3 to -7.47 mV, respectively. Encapsulation efficiencies were 9.68%, 10.99%, and 19.28% for cholecalciferol, calcifediol, and calcitriol, respectively. VD3-encapsulated NPs stimulated a dose-dependent increase in cathelicidin expression in THP-1 macrophages. Encapsulated calcifediol and calcitriol (100 ng/ml) induced the expression of 243.46 ng/ml ± 4.55 ng/ml and 396.67 ng/ml ± 25.24 ng/ml of cathelicidin, respectively, which was significantly higher than that induced by the free drugs. These findings suggest that NP encapsulation may offer a more efficient approach to using vitamin D3 for inducing cathelicidin expression as a host-directed treatment for TB.

31 Dec 2025·Environmental Pollutants and Bioavailability

Evaluating the influence of aquatic environmental hazard, polylactic acid microplastics, on Labeo rohita

Author: Al-Ghanim, Khalid A. ; Ali, Shafaqat ; Naeem, Adan ; Hussain, Syed Makhdoom ; Rashid, Eram ; Sarker, Pallab K.

This research sought to evaluate toxicity after intake of polylactic acid microplastics (PLA-MPs) on multiple parameters of Labeo rohita fingerlings, focusing on their growth, nutrient consumption, body composition, histopathol., hematol. and minerals status.Six test diets were formulated using sunflower meal (SFM) serving as the reference diet, incorporating different MPs concentrations: control (0%), 0.5%, 1%, 1.5%, 2% and 2.5% MPs.The formulated diets were administered to triplicate groups of 15 fish, with each fed at 5% weight (live wet) for 90 days duration.The outcomes revealed that the growth had significantly decreased in L. rohita fingerlings when exposed to PLA-MPs.Furthermore, the apparent nutrients digestibility reduced with the escalation in PLA-MPs levels.PLA-MP exposure led to substantial alterations in body composition, including enhanced body fat and reduced protein content.Furthermore, blood profile was also altered after the PLA-MPs exposure.Addnl., examination of gut histopathol. indicated an intensification in abnormalities in intestine at the 2.5% PLA-MPs concentrationThe diet having 2.5% MPs exhibited the min. body mineral compositionThis study suggests that exposure of PLA-MPs influenced the L. rohita health performance.

01 Dec 2025·IMMUNOLOGIC RESEARCH

Arginine vasopressin (AVP) treatment increases the expression of inhibitory immune checkpoint molecules in monocyte-derived dendritic cells

Article

Author: Naseri, Bahar ; Baradaran, Behzad ; Ghahramanipour, Zahra ; Sohrabi, Sepideh ; Karimzadeh, Hadi ; Mardi, Amirhossein ; Baghbani, Elham ; Masoumi, Javad

Arginine vasopressin (AVP) has disparate impacts on immune responses by divergent receptors on cells including DCs. This study was conducted with the aim of investigating the impact of AVP on the maturation and expression of the inhibitory immune checkpoint molecules in tolerogenic monocyte-derived DCs. CD14 marker was used to separate monocytes from peripheral blood mononuclear cells (PBMCs) by MACS method. To differentiate monocytes from DCs, we utilized GM-CSF and IL-4 cytokines. Tolerogenic DCs were generated using vitamin D3 and dexamethasone. We added LPS and AVP to the culture medium on day 6 after incubation of DCs at 37 °C. Finally, we assessed the surface molecules by flow cytometry and used real-time PCR to evaluate the expression of genes related to the inhibitory immune checkpoints. Based on the obtained data, AVP increased the expression of CD11c (P ≤ 0.0001), HLA-DR (P ≤ 0.01), and CD86 (P ≤ 0.01) in AVP-mDCs. Also, the expression of all the immune checkpoint genes including CTLA-4 (P ≤ 0.001), BTLA (P ≤ 0.001), PDL-1 (P ≤ 0.05), B7H7 (P ≤ 0.001), LAG3 (P ≤ 0.01), and VISTA (P ≤ 0.001) in AVP-mDCs was increased in comparison to the control group. Vasopressin caused the generation of mature and tolerogenic DCs. Our data may help to consider AVP-mDCs to take part in autoimmune disease therapy, transplanted tissue rejection impedance, and allergies.

154

News (Medical) associated with Colecalciferol

04 May 2025

·pharma.economictimes.indiatimes.com

Revoke licenses of pharma units that fail quality checks: Expert Committee

New Delhi: Drug manufacturers in India identified as producing Not of Standard Quality (NSQ) drugs may soon face suspension of their respective product manufacturing licenses. During the 92nd meeting of the Drugs Technical Advisory Board (DTAB)—comprising top-level policymakers and industry stakeholders—it was noted: “It is very important that once a drug is declared NSQ, the license of such a product shall be suspended immediately in the public interest.” According to the meeting details shared by the Central Drugs Standard Control Organisation (CDSCO), the DTAB recommended appropriate amendments to the Drug Rules. It further stated that a suspended product license should only be reinstated after a thorough root cause analysis and the implementation of corresponding Corrective and Preventive Action (CAPA). The matter came up for discussion following a proposal to suspend product permissions for batches declared NSQ by government analysts from official testing laboratories. As per government data, in FY 2023–24, 2,988 drug samples were declared Not of Standard Quality. Most recently, during its March 2024 quality inspections, central and state laboratories under the CDSCO flagged 131 drug samples as NSQ. While the quality review data for April is yet to be released, as of March, laboratories had flagged 379 NSQ drug samples, including paracetamol, vitamin D3 supplements, anti-diabetic pills, and medications for high blood pressure, among others. Some of the common reasons cited for flagging samples as NSQ include issues with dissolution, appearance of the solution, presence of visible particulate matter, and description. Currently, under Rule 143 of the Drugs and Cosmetics Rules, 1945, the Licensing Authority is empowered to suspend the license of any licensee who has failed to comply with the conditions of the license or any provisions of the Drugs and Cosmetics Act, 1940, or the rules framed thereunder. In 2023, it was reported that the Centre halted drug production at 31 firms and cancelled or suspended product licenses of 50 firms for non-compliance with quality control norms. However, according to the Health Ministry, “The failure is specific to the drug products of the batch tested by the government laboratory, and it does not warrant concerns about other drug products available in the market.” Every month, central and state drug testing laboratories assess the quality of drug batches collected by regulatory bodies. The identification of drug samples as NSQ is based on failure to meet one or more specified quality parameters. The term "Not of Standard Quality" is defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Online Bureau ,

23 Apr 2025

·www.prnewswire.com

ProRx Pharma Continues to Expand Preventative Health Portfolio with Six New Products

Expanded Product Line Targets Growing Demand for Proactive Wellness Solutions in Clinics, Med Spas, 503A Pharmacies, and Telehealth Practices Across the United States WEST PALM BEACH, Fla. and EXTON, Pa., April 23, 2025 /PRNewswire/ -- ProRx Pharma, the leading health and wellness 503B outsourcing facility, today announced the addition of six new injectable products designed to support the rising demand for preventive care: Gonadorelin, Liraglutide, Vitamin D3, and Phenylephrine HCl as well as two Tri-Mix injection options. These high-quality standalone injectables are now available for bulk shipping to licensed medical facilities in 26 states and for direct-to-consumer shipping nationwide through ProRx's growing network of 503A pharmacies, clinics, med spas and telehealth providers. "Patients are taking charge of their health like never before," said Kurt Lunkwitz, chief operating officer at ProRx. "Physicians are following suit, integrating wellness therapies into their practices to meet the demand for more proactive, functional care. This trend is only going to continue. The continued expansion of our health and wellness line is a direct response—and a step toward making preventative health more accessible and streamlined." What's New: The Products Each of the six new offerings comes with its own National Drug Code (NDC) number and an extended Beyond Use Date (BUD), providing both flexibility and longer shelf life for providers: Gonadorelin ( 1 mg/mL, 6 mg / 6 mL vial ) A gonadotropin-releasing hormone agonist which is used in fertility medicine and to treat amenorrhea and hypogonadism. Gonadorelin may promote testosterone production; may support fertility, libido, and hormonal balance. Liraglutide ( 0.75 mg, 1 mg, 2 mg, 3 mg [custom dosing] ) A powerful GLP-1 receptor agonist for weight and blood-sugar management. Liraglutide may aid in weight loss, appetite suppression, and blood-sugar control. Vitamin D3 ( 50,000 IU/mL, 5 mL vial ) A high-dose solution for those with critically low vitamin D levels. Vitamin D3 may support immune function, bone health, mood, and Vitamin D repletion. Tri-Mix #1 ( 30 mg / 1 mg / 10 mcg/mL, 5 mL vial ) The first of two strength offerings for erectile dysfunction (ED) therapy. Tri Mix #1 may improve erectile response through smooth muscle relaxation and blood flow. Tri-Mix #2 ( 30 mg / 2 mg / 20 mcg/mL, 5 mL vial ) A stronger ED therapy offering. Tri-Mix #2, may provide more ED support for patients needing increased vasodilation. Phenylephrine HCl ( 0.1% 2 mL vial) A critical safety solution for patients using Tri-Mix therapies. Phenylephrine HCl may reverse prolonged erection or priapism due to ED therapy. The introduction of these six new products comes on the heels of ProRx announcing its first four preventative-care offerings the first week of April: Sermorelin, NAD+, Glutathione and MIC/B6/B12. Exclusive Launch at A4M Conference ProRx is showcasing its full line of preventative-care products at the A4M 33rd Annual Spring Conference taking place April 24-26 in West Palm Beach, Florida. At Booth 527, attendees will get an exclusive first look at all 10 products in the new product line and be able to speak with ProRx's experts about the company's compliance and quality-assurance programs. About ProRx Pharma ProRx Pharma is an FDA-registered cGMP facility focused on providing essential compounded medications to meet the need for medications on the FDA drug shortage and bulks list with an emphasis on preventative health. The company produces products and formulations for medical institutions, physician offices, and 503A pharmacies, with a specialization in producing high-quality products to ensure patients have access to the medications they need during critical shortages. For more information, visit SOURCE ProRx Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

11 Apr 2025

·pharma.economictimes.indiatimes.com

41 faulty drugs recalled from market in Karnataka after deaths of new mothers

Bengaluru: Ever wondered if the medicines on your shelf are actually safe? The state drug administration department has recalled drugs worth Rs 24.3 lakh from the market because they weren't. In Feb and March, enforcement officers conducted a statewide check on medicine quality. They collected thousands of drug samples from pharmacies across the state and sent them to govt labs in Bengaluru, Hubballi , and Ballari for testing. In March alone, 1,891 samples were analysed, out of which 41 failed the test. The enforcement followed a series of deaths of new mothers following C-section procedures in Ballari District Hospital. The govt ordered lab tests of the drugs that had landed in its hospitals and were administered to patients. Ringer lactate infusion, a commonly used IV fluid, was found to have been administered to the women who later died. Out of 196 batches tested, 113 were declared substandard. This triggered 78 legal cases against the manufacturers. The drug control officers also inspected 2,078 medical shops across Karnataka, leading to the suspension of 215 drug licences due to various violations. Health minister Dinesh Gundu Rao said a total of 28 court cases were filed during Feb and March under the Drugs and Cosmetics Act, 1940. "We took legal action and recalled all 41 drugs that failed the quality tests," he said. The drugs that most commonly failed quality tests include formulations of paracetamol, sodium chloride injections, levocetirizine, azithromycin, metformin, vitamin D3, and iron-folic acid supplements. To strengthen safety measures, the govt is developing a software platform to track substandard drugs throughout the supply chain. "I've always stressed the need for a system that flags poor-quality drugs so they can be removed completely from the market," said Gundu Rao. "With public health being our priority, we are actively testing drugs and encouraging better coordination between states to share information on faulty batches." The upcoming platform will store details of retailers, wholesalers, manufacturers, and their authorised agents. "This will help us trace and eliminate substandard drugs at every stage more efficiently," the minister added, noting that the system will be rolled out soon. A senior official of the department explained, "While we do routine checks for drugs at regular intervals, following the increase in the number of substandard drugs in our checks, we are intensifying our routine tests to make sure we take strict action against the company or individual responsible for the poor-quality drug. Our goal is to have standard quality drugs to ensure public health safety. By exercising strict control and vigilance on the drugs marketed in the state, the department wants to eradicate the menace of spurious and substandard drugs, ensure the safety of drugs and their availability at controlled prices to the public." By Yashaswini Sri ,

100 Deals associated with Colecalciferol

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	China	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Hypoparathyroidism	Canada	-	01 Jan 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	Phase 3	South Korea	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	Italy	Abiogen Pharma SpA	01 Nov 2011
Hypercalcemia	Phase 3	Denmark	University of Aarhus	01 May 2008
Hyperparathyroidism, Primary	Phase 3	Denmark	University of Aarhus	01 May 2008
Crohn Disease	Phase 3	Denmark	University of Aarhus	01 Sep 2005
Lower urinary tract infectious disease	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Osteoporosis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Rheumatoid Arthritis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Diabetes Mellitus, Type 2	Phase 2	Denmark	University of Aarhus	01 Dec 2008
Complicated urinary tract infection	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04428359 (Pubmed \| Health Sci Rep)	Not Applicable	Warts	61	Intralesional MMR Vaccine	qbbadvxjfr(gqximpojop) = rare with MMR qyfflhrxzx (ajfqssfuah ) View more	Positive	01 May 2025
				Intralesional Vitamin D3
NCT02224144 (CTgov)	Phase 2	Bone Diseases, Metabolic \| Vascular Calcification \| Kidney Failure, Chronic ... View more	61	Calcitriol+Vitamin D3 (Vitamin D3 Plus Calcitriol)	qcfnsuevwl(nvpvxoqgyt) = ialdnbdrtx bwadmqmrke (dtznkikzgy, 0.54) View more	-	07 Mar 2025
				Placebo+Vitamin D3 (Vitamin D3 Plus Placebo)	qcfnsuevwl(nvpvxoqgyt) = nqdcuzrkqk bwadmqmrke (dtznkikzgy, 0.46) View more
NCT01748448 (ViDMe, CTgov)	Phase 3	Melanoma, Cutaneous Malignant	436	Vitamin D (Vitamin D)	vbxyedljyj = onqftdzsre kxwfzsuiau (evcuojpwze, mzzqtxxvwt - oymrnvpkwu) View more	-	17 Feb 2025
				Placebo: Oil (Placebo: Oil)	vbxyedljyj = hyiqgqbcse kxwfzsuiau (evcuojpwze, xbangeerfq - oasbcxpnkw) View more
NCT04780061 (CTgov)	Phase 3	COVID-19	90	Vitamin C/Zinc+Vitamin D3 (Treatment)	troatrqhdb(aesbhyucsd) = msivkpaunn iyjniqvwyu (pysmzzmvdc, 226.6) View more	-	19 Sep 2024
				Medium Chain Triglyceride Oil (Control)	troatrqhdb(aesbhyucsd) = iulknpratl iyjniqvwyu (pysmzzmvdc, 220.7) View more
NCT01443728 (CTgov)	Phase 2	Asthma \| Vitamin D Deficiency \| Acute Chest Syndrome ... View more	70	Vitamin D3 (Vitamin D3 100,000 IU)	iysqssdizr(ifaioxgjnq) = jydljhscpm heknkbewcu (sxluamdpfy, 0.35) View more	-	09 Aug 2024
				Vitamin D3 (Vitamin D3 12,000 IU)	iysqssdizr(ifaioxgjnq) = efvakdggpt heknkbewcu (sxluamdpfy, 0.35) View more
625-P (ADA2024)	Not Applicable	Diabetes Mellitus, Type 2 Vitamin D \| Thyroid function	730	Vitamin D (Lower VD group)	yciqschgmc(ammidxutcz) = euzmcjsovx jrrouvwpqx (otnqkniewz ) View more	Positive	14 Jun 2024
				Vitamin D (Higher VD group)	yciqschgmc(ammidxutcz) = ynpoeusuku jrrouvwpqx (otnqkniewz ) View more
EULAR2024	Not Applicable	Fibromyalgia Vitamin D levels	-	Vitamin D (Fibromyalgia Syndrome (FMS) patients)	fcumoaehfj(gbkocrxpgm) = byerwkkkto osmhkgjchf (ynfmbgniih )	Positive	05 Jun 2024
				Vitamin D (Healthy individuals)	fcumoaehfj(gbkocrxpgm) = pzbtemxmgo osmhkgjchf (ynfmbgniih )
EULAR2024	Not Applicable	Systemic Lupus Erythematosus	-	Vitamin D (SLE Female Patients)	cznnrhoths(rdwkvulwia) = mstchhpizj uielladswb (bzsmfakooa )	-	05 Jun 2024
				Vitamin D (Control Group)	cznnrhoths(rdwkvulwia) = qlwglzojpj uielladswb (bzsmfakooa )
ENDO2024	Not Applicable	Hypoparathyroidism	-	Vitamin D supplementation	cnpneiptxz(nlrhseedmq) = vxxclkvxcf mjepvjkrrg (ywylgraxzy )	-	01 Jun 2024
NCT01169259 (VITAL, ENDO2024)	Phase 3	Diabetes Mellitus, Type 2	-	Vitamin D 2000 IU/d	kttccenywi(bnidwrplmx) = kbeuupwzkv gkhdxikmcz (lkjgfrnwto )	Negative	01 Jun 2024
				Vitamin D (Placebo)	kttccenywi(bnidwrplmx) = cyfezmqnab gkhdxikmcz (lkjgfrnwto )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Colecalciferol

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation